期刊
EMBO MOLECULAR MEDICINE
卷 14, 期 3, 页码 -出版社
WILEY
DOI: 10.15252/emmm.202115295
关键词
fibrosis; MAPK inhibitors; melanoma; microRNA; nintedanib
资金
- Institut National de la Sante et de la Recherche Medicale (Inserm)
- Centre National de la Recherche Scientifique (CNRS)
- Ligue Contre le Cancer
- Fondation ARC
- Institut National du Cancer [INCA_12673]
- ITMO Cancer Aviesan (Alliance Nationale pour les Sciences de la Vie et de la Sante, National Alliance for Life Science and Health) [18CN045]
- French Government (National Research Agency, ANR) through the Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01, ANR-PRCI-18-CE92-0009-01 FIBROMIR]
- Conseil General 06
- Canceropole PACA
- Region Provence Alpes Cote d'Azur
- LABEX SIGNALIFE
- Fondation pour la Recherche Medicale
- La Ligue Contre le Cancer
- FWO [G.0929.16N]
- KULeuven
This study demonstrates that the anti-fibrotic drug nintedanib can normalize the fibrous ECM network, enhance the effectiveness of MAPK-targeted therapy, and delay tumor relapse in a preclinical model of melanoma. The miR-143/-145 pro-fibrotic cluster plays a crucial role in the acquisition of drug resistance, and the mature miRNAs, miR-143-3p and miR-145-5p, mediate the transition towards a drug-resistant undifferentiated mesenchymal-like state. Preventing the pro-fibrotic stromal response induced by MAPKi treatment presents a viable therapeutic opportunity for melanoma patients.
Lineage dedifferentiation toward a mesenchymal-like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the anti-fibrotic drug nintedanib is active to normalize the fibrous ECM network, enhance the efficacy of MAPK-targeted therapy, and delay tumor relapse in a preclinical model of melanoma. Acquisition of this resistant phenotype and its reversion by nintedanib pointed to miR-143/-145 pro-fibrotic cluster as a driver of this mesenchymal-like phenotype. Upregulation of the miR-143/-145 cluster under BRAFi/MAPKi therapy was observed in melanoma cells in vitro and in vivo and was associated with an invasive/undifferentiated profile. The 2 mature miRNAs generated from this cluster, miR-143-3p and miR-145-5p, collaborated to mediate transition toward a drug-resistant undifferentiated mesenchymal-like state by targeting Fascin actin-bundling protein 1 (FSCN1), modulating the dynamic crosstalk between the actin cytoskeleton and the ECM through the regulation of focal adhesion dynamics and mechanotransduction pathways. Our study brings insights into a novel miRNA-mediated regulatory network that contributes to non-genetic adaptive drug resistance and provides proof of principle that preventing MAPKi-induced pro-fibrotic stromal response is a viable therapeutic opportunity for patients on targeted therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据